Clinical Trial Update: Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing ocular safety of vorapaxar in participants with atherosclerosis has completed; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Ischemia
• Myocardial Infarction
• Stroke

Drugs mentioned

• Vorapaxar (SCH 530348) (vorapaxar)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Atherosclerosis, Ischemia | Phase 3 | Status: COMPLETED | Results posted: 2014-07-14